SyntheticMR 将来の成長

Future 基準チェック /56

SyntheticMR利益と収益がそれぞれ年間47.4%と18.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に29.5% 47.4%なると予測されています。

主要情報

47.4%

収益成長率

47.4%

EPS成長率

Healthcare Services 収益成長	30.1%
収益成長率	18.8%
将来の株主資本利益率	29.5%
アナリストカバレッジ	Low
最終更新日	21 Feb 2024

今後の成長に関する最新情報

Recent updates

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Nov 29

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Aug 06

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Feb 23

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Jan 27

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Nov 10

Read This Before Selling SyntheticMR AB (publ) (NGM:SYNT) Shares

Mar 09

What Percentage Of SyntheticMR AB (publ) (NGM:SYNT) Shares Do Insiders Own?

Feb 11

SyntheticMR AB (publ) (NGM:SYNT) Insiders Increased Their Holdings

Dec 03

業績と収益の成長予測

NGM:SYNT - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	181	55	47	N/A	1
12/31/2025	145	39	28	N/A	1
12/31/2024	112	23	8	N/A	1
12/31/2023	94	10	-17	-7	N/A
9/30/2023	85	6	-19	-9	N/A
6/30/2023	83	6	-26	-15	N/A
3/31/2023	80	7	-28	-17	N/A
12/31/2022	74	6	-26	-15	N/A
9/30/2022	71	8	-19	-9	N/A
6/30/2022	65	7	-12	-4	N/A
3/31/2022	58	2	-6	0	N/A
12/31/2021	63	8	-1	4	N/A
9/30/2021	60	8	-1	3	N/A
6/30/2021	57	5	-8	-3	N/A
3/31/2021	55	3	-9	-3	N/A
12/31/2020	52	1	-14	-9	N/A
9/30/2020	47	-6	-14	-9	N/A
6/30/2020	48	-3	-5	-1	N/A
3/31/2020	51	2	-2	3	N/A
12/31/2019	48	4	9	13	N/A
9/30/2019	53	12	11	14	N/A
6/30/2019	52	13	15	18	N/A
3/31/2019	50	14	18	21	N/A
12/31/2018	51	15	15	18	N/A
9/30/2018	49	14	16	19	N/A
6/30/2018	45	12	12	15	N/A
3/31/2018	39	8	11	14	N/A
12/31/2017	38	8	8	11	N/A
9/30/2017	34	8	N/A	11	N/A
6/30/2017	30	7	N/A	9	N/A
3/31/2017	28	6	N/A	6	N/A
12/31/2016	22	2	N/A	4	N/A
9/30/2016	15	1	N/A	0	N/A
6/30/2016	14	4	N/A	-1	N/A
3/31/2016	11	1	N/A	-3	N/A
12/31/2015	9	0	N/A	-5	N/A
9/30/2015	7	-4	N/A	-5	N/A
6/30/2015	5	-9	N/A	-6	N/A
3/31/2015	5	-8	N/A	-4	N/A
12/31/2014	4	-7	N/A	-3	N/A
9/30/2014	5	-6	N/A	-3	N/A
6/30/2014	5	-5	N/A	-3	N/A
3/31/2014	5	-5	N/A	-3	N/A
12/31/2013	4	-5	N/A	-4	N/A
9/30/2013	4	-4	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SYNTの予測収益成長率 (年間47.4% ) は貯蓄率 ( 0.9% ) を上回っています。

収益対市場: SYNTの収益 ( 47.4% ) はSwedish市場 ( 15.2% ) よりも速いペースで成長すると予測されています。

高成長収益: SYNTの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: SYNTの収益 ( 18.8% ) Swedish市場 ( 0.05% ) よりも速いペースで成長すると予測されています。

高い収益成長: SYNTの収益 ( 18.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SYNTの自己資本利益率は、3年後には高くなると予測されています ( 29.5 %)

SyntheticMR 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 28%

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 17%

Consensus EPS estimates increase by 18%

Consensus EPS estimates fall by 14%

Recent updates

SyntheticMR AB Receives Regulatory Approval for SyMRI 15 in Australia

SyntheticMR AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

SyntheticMR Announces Appointment of Francois Hebert as New President, North America

SyntheticMR Receives Regulatory Approval for Symri in Taiwan

SyntheticMR AB (publ) to Report Q2, 2024 Results on Aug 27, 2024

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11

SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow

SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea

Consensus EPS estimates fall by 28%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Some Investors May Be Worried About SyntheticMR's (NGM:SYNT) Returns On Capital

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Full year 2022 earnings released: EPS: kr0.15 (vs kr0.20 in FY 2021)

Now 24% undervalued after recent price drop

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

Consensus EPS estimates fall by 17%

Now 21% undervalued after recent price drop

SyntheticMR AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023

Now 20% undervalued after recent price drop

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Now 21% undervalued after recent price drop

SyntheticMR Receives EU Medical Device Regulation (Mdr) Certificate

SyntheticMR AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil

Consensus EPS estimates increase by 18%

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

Consensus EPS estimates fall by 14%

Consensus EPS estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

SyntheticMR AB (publ) to Report First Half, 2022 Results on Aug 23, 2022

SyntheticMR's Quantitative MRI Solution Symri Neuro Compatible with Philips Smartspeed to Support Shorter Scan Times

Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board

SyMRI MSK from SyntheticMR is Now Available on syngo.via Open Apps from Siemens Healthineers

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 19%

Price target decreased to kr36.00

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

SyntheticMR AB (publ), Annual General Meeting, May 10, 2022

SyntheticMR AB (publ) to Report Q1, 2022 Results on May 10, 2022

Now 24% undervalued after recent price drop

Syntheticmr AB (Publ) Announces Net Sales Guidance for the First Quarter 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)